

ISSCR Annual Meeting 2018 Innovation Showcase Session

Presented on Thursday, June 21, 2018 at 11:30 AM-12:30 PM

Room 105, Level 1

Biolaminin™ 521 CTG – a biologically relevant culture matrix, enabling pre-clinical research protocols to be translated and used for clinical trials

Kristian Tryggvason, CEO, BioLamina, Sweden

Malin Parmar, Professor, Lund University, Sweden

Fredrik Lanner, Assistant Professor, Karolinska Institute and Karolinska University Hospital, Sweden

As a complement to our portfolio of defined and xeno-free laminin stem cell substrates, we now offer a cell therapy grade (CTG) Biolaminin 521 cell culture substrate For Research Use or Non-commercial Manufacturing of Cell, Gene, or Tissue-Based Products. Biolaminin 521 CTG (CT521) has been developed and manufactured to allow customers to qualify the material for use in the manufacturing of cells for clinical research. USP Chapter 1043: Ancillary materials for cell, gene and tissue-engineered products has been considered in the design of the product. The product is animal origin component free and has supporting documentation, such as Certificate of Analysis, Animal Origin Free Statement and Bill of Material provided with every lot to support regulatory filings.

CT521 is a full-length, human, recombinant laminin 521 substrate, the only one of its kind on the market, providing an optimal environment for feeder-free culture of human PSCs, MSCs and most anchorage-dependent progenitor cell types. With this new clinical grade product, scientists are supported throughout their cell therapy development process – from concept to commercialized therapy. It recreates a biologically relevant milieu *in vitro*, promoting high survival and robust expansion of hPSCs, and subsequent cell lineage specification. The cells grow in a homogeneous monolayer, easy to monitor. The substrate is flexible and compliant with any cell culture medium. It allows an operator-independent culture maintenance and reliable, standardized protocols which can easily be adapted to automation platforms.

